Reliability of Droplet Digital PCR Alone and in Combination with Interleukin-6 and Procalcitonin for Prognosis of Bloodstream Infection
Sheng Yin,YingRui Lin,Bingqi Wang,Yizhi Peng,Zeyou Wang,Xiaolin Zhu,Hao Liang,Xianping Li,Min Wang
DOI: https://doi.org/10.2147/idr.s439683
2024-03-15
Infection and Drug Resistance
Abstract:Sheng Yin, 1 YingRui Lin, 1 Bingqi Wang, 1 Yizhi Peng, 2 Zeyou Wang, 1 Xiaolin Zhu, 1 Hao Liang, 1 Xianping Li, 1 Min Wang 1 1 Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China; 2 Department of Laboratory Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410031, People's Republic of China Correspondence: Min Wang, Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China, Tel +86 13298697558, Email Purpose: Bloodstream infection(BSI) is linked with high mortality, underscoring the significance of prompt etiological diagnosis for timely and precise treatment. This study aims to investigate the diagnostic value of droplet digital polymerase chain reaction(ddPCR) in combination with conventional inflammatory markers [interleukin-6(IL-6) and procalcitonin(PCT)] concerning disease progression and treatment prognosis in BSI patients. Furthermore, the study aims to explore a more efficient clinical application strategy. Patients and Methods: This prospective case seried study centers on 176 patients suspected of or confirmed with BSI. Blood samples were collected to extract nucleic acids for identifying pathogens (bacteria, fungi, and viruses) and determining copy loads via ddPCR. Results: The sensitivity of ddPCR was markedly higher compared to the culture method (74.71% vs 31.03%). A positive correlation existed between bacterial load and levels of inflammatory markers [IL-6 ( P= 0.0182), PCT ( P= 0.0029), and CRP ( P= 0.0005)]. In suspected BSI cases, the combination of ddPCR and inflammatory markers could predict sepsis risk [ROC: Area under the curve(AUC)=0.6071, P= 0.0383]. Within confirmed BSI patients, the ddPCR bacterial load of those with SOFA< 7 was lower than that of the SOFA≥ 7 ( P= 0.0334). ddPCR (OR: 1.789, P= 0.035) monitoring combined with PCT (OR: 1.787, P= 0.035) holded predictive value for SOFA progression (AUC=0.7913, P= 0.0003). Similarly, BSI survivors displayed a lower burden than non-survivors ( P= 0.0170). Additionally, ddPCR combinated with IL-6 provided a more accurate and expedited insight into clinical outcomes prediction for BSI confirmed patients (AUC=0.7352, P= 0.0030). Serial monitoring of bacterial load by ddPCR effectively mirrored the clinical course of BSI in patients. Notably, patients with positive ddPCR virus infection exhibited significantly reduced lymphocyte counts ( P= 0.0003). Conclusion: In a clinical context, qualitative ddPCR results and quantitative continuous monitoring can more precisely assess sepsis progression and treatment prognosis in BSI patients. Furthermore, ddPCR results offer quicker and more accurate reference points for clinical antibacterial and antiviral interventions. Keywords: bloodstream infection, droplet digital polymerase chain reaction, interleukin-6, procalcitonin, prognosis Bloodstream infection(BSI) in the intensive care unit has garnered significant clinical attention due to its high mortality rate. This is particularly relevant during the COVID-19 epidemic, as patients with severe pneumonia are susceptible to developing severe BSI, which may culminate in sepsis. 1,2 Globally, an estimated 48.9 million patients succumb annually to BSI. However, current empiric treatment options for bacterial infections have limited efficacy, and the indiscriminate use of broad-spectrum antibiotics can lead to severe economic and health burdens on both patients and society. 3 The diagnosis of BSI is currently mainly based on blood culture, which is considered the gold standard. However, the accuracy of blood culture results can be affected by several factors, including the number of blood pathogens, the timing and site of sampling, as well as various culture-related conditions such as culture time and environmental factors. 4 In addition, the process of bacterial enrichment and plate inoculation required for blood culture, coupled with the need for mass spectrometry for accurate identification, contributes to a turnaround time(TAT) of more than five days for the official final report. Unfortunately, this long waiting time forces clinicians to rely on broad-spectrum drug resistance measures based on the patient's condition and prior experience, leaving a significant proportion of patients with ineffective treatment. This situation is particularly dire for patients with sepsis in the intensive care unit, who may succumb to uncontrolled BSI th -Abstract Truncated-
pharmacology & pharmacy,infectious diseases